Abstract:Patients with multiple sclerosis (MS) often take multiple drugs at the same time to modify the course of disease, alleviate neurological symptoms and manage co-existing conditions. A major consequence for a patient taking different medications is a higher risk of treatment failure and side effects. This is because a drug may alter the pharmacokinetic and/or pharmacodynamic properties of another drug, which is referred to as drug-drug interaction (DDI). We aimed to predict interactions of drugs that are used by patients with MS based on a deep neural network (DNN) using structural information as input. We further aimed to identify potential drug-food interactions (DFIs), which can affect drug efficacy and patient safety as well. We used DeepDDI, a multi-label classification model of specific DDI types, to predict changes in pharmacological effects and/or the risk of adverse drug events when two or more drugs are taken together. The original model with ~34 million trainable parameters was updated using >1 million DDIs recorded in the DrugBank database. Structure data of food components were obtained from the FooDB database. The medication plans of patients with MS (n = 627) were then searched for pairwise interactions between drug and food compounds. The updated DeepDDI model achieved accuracies of 92.2% and 92.1% on the validation and testing sets, respectively. The patients with MS used 312 different small molecule drugs as prescription or over-the-counter medications. In the medication plans, we identified 3748 DDIs in DrugBank and 13,365 DDIs using DeepDDI. At least one DDI was found for most patients (n = 509 or 81.2% based on the DNN model). The predictions revealed that many patients would be at increased risk of bleeding and bradycardic complications due to a potential DDI if they were to start a disease-modifying therapy with cladribine (n = 242 or 38.6%) and fingolimod (n = 279 or 44.5%), respectively. We also obtained numerous potential interactions for Bruton's tyrosine kinase inhibitors that are in clinical development for MS, such as evobrutinib (n = 434 DDIs). Food sources most often related to DFIs were corn (n = 5456 DFIs) and cow's milk (n = 4243 DFIs). We demonstrate that deep learning techniques can exploit chemical structure similarity to accurately predict DDIs and DFIs in patients with MS. Our study specifies drug pairs that potentially interact, suggests mechanisms causing adverse drug effects, informs about whether interacting drugs can be replaced with alternative drugs to avoid critical DDIs and provides dietary recommendations for MS patients who are taking certain drugs.

Deep learning improves prediction of drug–drug and drug–food interactions

Deep learning for drug‐drug interaction prediction: A comprehensive review

DeepDrug: A General Graph-Based Deep Learning Framework for Drug-Drug Interactions and Drug-Target Interactions Prediction

Novel deep learning model for more accurate prediction of drug-drug interaction effects

DeSIDE-DDI: interpretable prediction of drug-drug interactions using drug-induced gene expressions

DPDDI: a deep predictor for drug-drug interactions

A Novel Deep Learning Model for Drug-drug Interactions

Multitype drug interaction prediction based on the deep fusion of drug features and topological relationships

Comprehensive evaluation of deep and graph learning on drug–drug interactions prediction

SSF-DDI: a deep learning method utilizing drug sequence and substructure features for drug–drug interaction prediction

DSN-DDI: an accurate and generalized framework for drug–drug interaction prediction by dual-view representation learning

Comprehensive evaluation of deep and graph learning on drug-drug interactions prediction

Novel deep learning-based transcriptome data analysis for drug-drug interaction prediction with an application in diabetes

Update and Application of a Deep Learning Model for the Prediction of Interactions between Drugs Used by Patients with Multiple Sclerosis

AMDE: a novel attention-mechanism-based multidimensional feature encoder for drug–drug interaction prediction

An effective framework for predicting drug–drug interactions based on molecular substructures and knowledge graph neural network

Deep Learning for High-Order Drug-Drug Interaction Prediction

Synergizing Convolutional Neural Networks and Drug Similarity Estimation for Improved Drug-Drug Interaction Prediction

Analysis and prediction of drug–drug interaction by minimum redundancy maximum relevance and incremental feature selection

Directed graph attention networks for predicting asymmetric drug–drug interactions

Drug-Drug Interaction Prediction Based on Knowledge Graph Embeddings and Convolutional-LSTM Network